An interventional study of Telephone based interview and Survey using a questionnaire. in Stage I Lung Cancer, Stage II Lung Cancer and Stage III Lung Cancer, sponsored by Wake Forest University Health Sciences. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences — 3 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Wake Forest University Health Sciences.
Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, this one is the 28th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 34th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →3 of the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 50–77
Wake Forest University Health Sciences · Sites in United States
Ages 40–54 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 3
First in 1998; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 46 across the 31 interventional studies, 55 across the 5 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
3 of the studies in Lung Neoplasms by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06383988Wake Forest University Health SciencesA Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources | 2026-12-30 |
| NCT07322367Wake Forest University Health SciencesA Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients | 2027-01 |
| NCT07282444Wake Forest University Health SciencesA New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial evaluates whether a shared response plan (SHAREDCare) improves follow-up care for lung cancer survivors. As the number of cancer survivors increases, there is a new need for high-quality chronic illness care. High-quality chronic illness care can be difficult to deliver and involves working with the patient to be certain they have what they need to be actively involved with their care to meet their needs. SHAREDCare allows the patient to work with a navigator to review identified distress and social needs. The patient and navigator discuss the needs and develop a shared response plan to address the needs in ways that consider the patient's current behaviors, beliefs, and motivation. The plan also establishes specific patient goals, anticipates barriers, and establishes how the navigator will follow-up on the needs and adjust care and assistance when needed. Using a shared response plan may improve follow-up care for lung cancer survivors.
Primary Objective: Pilot and qualitatively assess the acceptability of SHAREDCare through semi- structured interviews
Secondary Objectives:
OUTLINE:
Patients receive a SHAREDCare call with a navigator to discuss identified distress and social needs and develop/deploy a shared response plan to address identified needs on study. Patients also receive standard of care automated referrals on study. Two weeks following the initial call, patients receive a second SHAREDCare call with a navigator to follow-up on the shared response plan.
After completion of study intervention, patients are followed up 4 weeks after initial call.
Inclusion Criteria:
Exclusion Criteria: Does not meet the above inclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive a SHAREDCare call with a navigator to discuss identified distress and social needs and develop/deploy a shared response plan to address identified needs on study. Patients also receive standard of care automated referrals on study. Two weeks following the initial call, patients receive a second SHAREDCare call with a navigator to follow-up on the shared response plan.
Behavioral: Telephone based interview · Other: Survey using a questionnaire. · Other: Electronic health record review · Other: Referral
Receive SHAREDCare navigator calls
Ancillary studies
Ancillary studies
Receive standard of care automated referrals
SHAREDCare's Qualitative Acceptability
Will be assessed with semi-structured interviews. These methods will be guided by Grounded Theory, a process using inductive coding to develop theory from data (e.g., themes relating to components, timing, or delivery of the intervention).
Time frame: At 4 weeks post-initial call
SHAREDCare's Quantitative Acceptability
Measured using the Acceptability of Intervention Measure (AIM), a 4-item instrument assessing perceived acceptability of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater acceptability. The overall AIM score is calculated as the mean of the four items and ranges from 1 to 5.
Time frame: At 4 weeks post-initial call
SHAREDCare's Quantitative Feasibility
Measured using the Feasibility of Intervention Measure (FIM), a 4-item instrument assessing the perceived feasibility of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater feasibility. The overall FIM score is calculated as the mean of the four items and ranges from 1 to 5.
Time frame: At 4 weeks post-initial call
SHAREDCare's Quantitative Appropriateness
Measured using the Intervention Appropriateness Measure (IAM), a 4-item instrument assessing perceived appropriateness of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater appropriateness. The overall IAM score is calculated as the mean of the four items and ranges from 1 to 5.
Time frame: At 4 weeks post-initial call
Total Survivor Unmet Needs Survey Score
Measured using the Survivor Unmet Needs Survey, a 30-item instrument assessing cancer survivors' unmet supportive care needs. Each item is scored from 0 (no unmet need) to 4 (very high unmet need). Item scores are summed to create a total score ranging from 0 to 120, with higher scores indicating greater unmet needs and a worse outcome. Total scores were assessed at baseline and 4 weeks post-initial call
Time frame: At baseline and at 4 weeks post-initial call
Number of Clinical Referrals Made
Total number of referrals generated during the SHAREDCare intervention, including referrals to supportive care services such as tobacco cessation, nutrition, health coaching, financial navigation, and palliative care.
Time frame: At 4 weeks post-initial call
Number of Referrals Completed
Defined as those referrals where a patient self-reported completing visit through 4 weeks post-initial call.
Time frame: At 4 weeks post-initial call
Number of Participants Enrolled
The number of eligible participants enrolled in the study was assessed. Reasons for non-enrollment among eligible participants were recorded and summarized descriptively.
Time frame: During study recruitment over 5 months
Percentage of Participants With Completion of All Follow-up Visits
Retention was assessed as the percentage of enrolled participants who completed all planned follow-up assessments through the end of study participation.
Time frame: Through 4 weeks post-initial call
| Milestone | SHAREDCare Supportive Care Arm |
|---|---|
| Started | 5 |
| Completed | 5 |
| Not completed | 0 |
Will be assessed with semi-structured interviews. These methods will be guided by Grounded Theory, a process using inductive coding to develop theory from data (e.g., themes relating to components, timing, or delivery of the intervention).
| Participants | SHAREDCare Supportive Care Arm |
|---|---|
| SHAREDCare meets approval | 5 |
| SHAREDCare is appealing | 5 |
| SHAREDCare is liked | 5 |
| SHAREDCare is welcomed | 5 |
| Patients value coordinated support, but role fit, timing, and screening alignment concerns exist | 5 |
Measured using the Acceptability of Intervention Measure (AIM), a 4-item instrument assessing perceived acceptability of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater acceptability. The overall AIM score is calculated as the mean of the four items and ranges from 1 to 5.
| score on a scale | SHAREDCare Supportive Care Arm |
|---|---|
| SHAREDCare's Quantitative Acceptability | 4.25 ± 0.43 |
Measured using the Feasibility of Intervention Measure (FIM), a 4-item instrument assessing the perceived feasibility of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater feasibility. The overall FIM score is calculated as the mean of the four items and ranges from 1 to 5.
| score on a scale | SHAREDCare Supportive Care Arm |
|---|---|
| SHAREDCare's Quantitative Feasibility | 4.20 ± 0.45 |
Measured using the Intervention Appropriateness Measure (IAM), a 4-item instrument assessing perceived appropriateness of an intervention. Each item is rated on a 1-5 Likert scale, with higher scores indicating greater appropriateness. The overall IAM score is calculated as the mean of the four items and ranges from 1 to 5.
| score on a scale | SHAREDCare Supportive Care Arm |
|---|---|
| SHAREDCare's Quantitative Appropriateness | 4.10 ± 0.55 |
Measured using the Survivor Unmet Needs Survey, a 30-item instrument assessing cancer survivors' unmet supportive care needs. Each item is scored from 0 (no unmet need) to 4 (very high unmet need). Item scores are summed to create a total score ranging from 0 to 120, with higher scores indicating greater unmet needs and a worse outcome. Total scores were assessed at baseline and 4 weeks post-initial call
| Scores on a scale | SHAREDCare Supportive Care Arm |
|---|---|
| Scores on a scale reported at baseline | 9.6 ± 13.3 |
| Scores on a scale reported at 4-weeks post initial call | 10.2 ± 13.5 |
Total number of referrals generated during the SHAREDCare intervention, including referrals to supportive care services such as tobacco cessation, nutrition, health coaching, financial navigation, and palliative care.
| Referrals | SHAREDCare Supportive Care Arm |
|---|---|
| Number of Clinical Referrals Made | 7 |
Defined as those referrals where a patient self-reported completing visit through 4 weeks post-initial call.
| Self-reported completed referrals | SHAREDCare Supportive Care Arm |
|---|---|
| Number of Referrals Completed | 8 |
The number of eligible participants enrolled in the study was assessed. Reasons for non-enrollment among eligible participants were recorded and summarized descriptively.
| Participants | SHAREDCare Supportive Care Arm |
|---|---|
| Number of Participants Enrolled | 5 |
Retention was assessed as the percentage of enrolled participants who completed all planned follow-up assessments through the end of study participation.
| Participants | SHAREDCare Supportive Care Arm |
|---|---|
| Percentage of Participants With Completion of All Follow-up Visits | 5 |
Collected over Baseline through 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SHAREDCare Supportive Care Arm | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Age, Customized(Age in Years) | SHAREDCare Supportive Care Arm |
|---|---|
| Mean age in years | 70.8 ± 9.1 |
| Sex: Female, Male(Participants) | SHAREDCare Supportive Care Arm |
|---|---|
| Female | 4 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | SHAREDCare Supportive Care Arm |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | SHAREDCare Supportive Care Arm |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 3 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2025 to primary completion in Jan 2026, 7 months.
Results were first posted in Oct 2026, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →